What ADT Does to the Body
Androgen deprivation therapy (ADT) is a standard treatment for locally advanced or metastatic prostate cancer. It works by reducing testosterone levels to slow cancer growth. But testosterone also plays a central role in how the body manages fat storage, muscle mass, and blood sugar. When it falls sharply, a series of metabolic changes can follow.
Men on ADT tend to accumulate body fat – especially around the abdomen – while losing lean muscle mass. This shift in body composition can happen even when total body weight stays roughly the same. Over months and years, it contributes to higher blood sugar levels, worsened cholesterol profiles, and elevated blood pressure. When three or more of these changes occur together, they meet the definition of metabolic syndrome.
| Axis | Metformin | Structured Exercise | Diet Modification |
|---|---|---|---|
| Dose or approach studied in ADT trials | 500 mg three times daily or 850 mg twice daily | Combined aerobic and resistance training | Low-glycaemic, calorie-aware eating patterns |
| Strength of evidence in ADT patients | Phase 2 and Phase 3 randomised controlled trials | Multiple randomised trials in cancer survivors | Mainly observational studies and expert consensus |
| Primary metabolic target | Insulin resistance and hepatic glucose output | Body composition and insulin sensitivity | Post-meal blood sugar and energy balance |
| Key practical consideration | Prescription required; kidney function must be assessed beforehand | Requires sustained adherence to deliver benefit | Highly variable response between individuals |
Metformin doses cited from the phase II randomised trial (PMC10278660) and the PRIME phase III trial (PMID 40711960). Exercise and diet rows are qualitative summaries drawn from published reviews in the same patient population.
A 2015 meta-analysis published in PLOS ONE pooled data from multiple studies and found that men receiving ADT had a relative risk of 1.75 for developing metabolic syndrome compared with men not on ADT. The same analysis found a relative risk of 1.36 for developing type 2 diabetes during or after ADT. These are meaningful increases in risk for a treatment that many men continue for months or years at a time.
The changes can appear quickly. Insulin resistance develops within six to eight weeks of starting ADT. It is one of the earliest signs of blood sugar trouble, according to a review of ADT metabolic consequences published via NCBI (NIH). Over the longer term, a further analysis found that more than half of men on long-term ADT develop metabolic syndrome, a figure that shows how common this side effect really is.
What Is Metabolic Syndrome?
Metabolic syndrome is not a single disease. It is a group of five conditions that, when three or more occur together, raise the risk of heart disease, stroke, and type 2 diabetes. In men, those five conditions are:
- A waist circumference above 102 cm (40 inches)
- Fasting triglycerides of 150 mg/dL or higher
- HDL cholesterol below 40 mg/dL
- Blood pressure of 130/85 mmHg or higher
- Fasting blood glucose of 100 mg/dL or higher
For men with prostate cancer, metabolic syndrome matters beyond general health. Cardiovascular disease is one of the leading causes of death in this population – in some analyses, it rivals the cancer itself as a mortality driver. A treatment that helps control the cancer while accelerating heart disease creates a genuine problem for long-term care planning, which is why oncology teams are now paying closer attention to metabolic monitoring during ADT.
ADT also alters oestrogen metabolism in men, adding another layer of hormonal disruption beyond the drop in testosterone. The article on estrogen rebalancing after prostate cancer ADT covers how those hormonal changes play out and what the evidence currently supports for managing them.
How Metformin May Help
Metformin is one of the most widely prescribed medications for type 2 diabetes. It has been in clinical use for decades and is safe and well-tested. It works primarily by reducing the amount of glucose the liver releases into the bloodstream. This lowers circulating blood sugar without directly triggering additional insulin secretion – which matters because high circulating insulin is itself a driver of fat storage and metabolic stress.
Metformin also activates an enzyme called AMPK (adenosine monophosphate-activated protein kinase), which acts as a cellular energy sensor. When AMPK is activated, it inhibits a signaling molecule called mTOR, which plays a role in both cell growth and how the body uses energy. Reducing insulin resistance while inhibiting mTOR may help patients whose cancer treatment raises metabolic risk.
For ADT patients, metformin might work by keeping insulin lower and improving blood sugar control, which could partially counteract the fat buildup and blood sugar problems that ADT causes. Researchers are still studying this question. It is not yet a standard clinical recommendation.
What the Clinical Trials Show
Researchers have tested this idea directly in patients with prostate cancer who were starting ADT and did not have diabetes.
A randomised, double-blind phase II trial enrolled non-diabetic men with biochemically-relapsed or advanced prostate cancer who were beginning ADT. Participants received either metformin at 500 mg three times daily or a matched placebo. This trial, published in 2023 and available at PubMed Central, found early signs that metformin may reduce the development of metabolic syndrome during ADT. The results were preliminary. Larger studies would be needed before doctors could make clinical recommendations based on this.
The PRIME study was the larger phase III follow-up. This multicenter, double-blind, randomised controlled trial assigned patients without high blood sugar who were planned for at least nine months of ADT to receive either metformin 850 mg twice daily or placebo for 18 months, in a 2:1 randomisation. The trial enrolled 166 patients before it closed early because of a drug supply disruption unrelated to patient safety. Results, published in 2025 and available at PubMed, point to possible benefits of metformin, though the early closure makes the findings less certain.
A 2024 systematic review and meta-analysis, available at PubMed, brought together data from available trials. The authors concluded that metformin may help certain metabolic markers in ADT-treated prostate cancer patients, and called for larger, more standardised trials before firm recommendations can be issued.
Metformin’s role in integrative oncology is being studied across multiple cancer types. The article on metformin during breast cancer: dosing and supplement safety covers the evidence in that setting and identifies supplement interactions that clinicians have flagged – a useful reference for caregivers managing more than one patient in the household.
Dosing in Trials and What to Know About Safety
The doses used in ADT trials fell within the standard therapeutic range for metformin. The phase II trial used 500 mg three times daily, and the PRIME trial used 850 mg twice daily. According to the NIH StatPearls monograph on metformin, treatment is typically started at 500 mg once or twice daily and titrated weekly in increments of 500 or 850 mg. That gradual titration is recommended specifically to minimize gastrointestinal side effects, which are the most common reason patients stop taking the medication early.
The most serious risk associated with metformin is lactic acidosis, a rare but potentially severe condition involving a buildup of lactic acid in the blood. The NIH StatPearls monograph notes that lactic acidosis occurs in approximately three of every 100,000 patient-years of metformin use, and that risk rises substantially in people with compromised kidney, liver, or cardiac function. Baseline renal function testing is standard practice before starting metformin, with periodic monitoring continuing throughout treatment.
Metformin is a prescription medication. It should not be started without a prescribing clinician who can assess kidney and liver function, screen for drug interactions, and monitor metabolic response over time.
Exercise and Diet as Complementary Strategies
In the trials described above, metformin was studied as an addition to standard care, not instead of lifestyle changes. A review of exercise-based interventions and metabolic syndrome in prostate cancer patients, published via NCBI, found that regular aerobic and resistance training improves body composition and metabolic markers in this population. Combining both training types provides more benefit than either alone.
Dietary changes that reduce glycaemic load – such as limiting refined carbohydrates, increasing fiber intake, and cutting added sugars – may help stabilize blood sugar throughout the day. Neither exercise nor diet alone can fully reverse ADT-related metabolic syndrome in all men. That’s why researchers study metformin as an addition to lifestyle changes, not a replacement.
Monitoring During ADT
Men starting ADT should ask their oncology team about baseline metabolic testing before treatment begins. A standard starting panel typically includes fasting blood glucose, HbA1c, a lipid profile, blood pressure measurement, and waist circumference. These measurements create a baseline that makes it much easier to spot meaningful trends at follow-up appointments.
Repeat testing every three to six months is common for men on active ADT. If fasting glucose rises, triglycerides worsen, or abdominal fat increases measurably between appointments, the care team can weigh whether a structured exercise referral, dietary support, or a pharmacological option like metformin is the appropriate next step for that individual.
Talk with your oncology team about monitoring metabolic markers and whether medications like metformin may be right for you.
If you are on prescription medication, pregnant, or breastfeeding, speak with your clinician before making any changes to your treatment or adding supplements to your routine. This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
